Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment

References

• Knochenhauer E S, Key T J, Kahsar-Miller M, Wagner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women in the Southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods K S, Reyna R, Key J, Knochenhauer S, Yldiz B. Prevalence and features of the polycystic ovary syndrome in unselected population. J Clin Endocrinol Metab 2004; 89: 2745–2749
   PubMed Web of Science ®Google Scholar
• Lo J C, Feigenbaum S L, Yang J, Pressman A R, Selby J V, Go A S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1357–1363
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reprod 2004; 19: 41–47
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–1174
   PubMed Web of Science ®Google Scholar
• Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165–169
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Johansson S, Lindstedt G, Knuttson F, Oden A, Jonson P O, Mattson L A, Crona N, Lundberg P A. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57: 505–513
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H S. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595–600
   PubMed Web of Science ®Google Scholar
• Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal woman with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15: 785–789
   PubMed Web of Science ®Google Scholar
• Blake G J, Ridker P M. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763–771
   PubMed Web of Science ®Google Scholar
• Pearson T A, Mensah G A, Alexander R W, Anderson J L, Cannon R O, 3rd, Criqui M, Fadl Y Y, Fortmann S P, Hong Y, Myers G L, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511
   PubMed Web of Science ®Google Scholar
• Ridker P M, Hennekens C H, Buring J E, Rifai N. C-reactive protein and other markers of inflammation in the predictor of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843
   PubMed Web of Science ®Google Scholar
• Ridker P M, Buring J E, Shih J, Matias M, Hennekens C H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731–733
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy R P, Haffner S M. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study. Circulation 2000; 102: 42–47
   PubMed Web of Science ®Google Scholar
• Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160–2165
   PubMed Web of Science ®Google Scholar
• Kelly C, Lyall H, Petrie J R, Gould G Z, Connell J MC, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453–2455
   PubMed Web of Science ®Google Scholar
• Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003; 80: 123–127
   PubMed Web of Science ®Google Scholar
• Talbott E O, Zborowski J V, Bourdeaux M Y, Mc Hugh-Pemu K P. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 6061–6067
   PubMed Web of Science ®Google Scholar
• Tarkun I, Arslan B C, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592–5596
   PubMed Web of Science ®Google Scholar
• Puder J J, Varga S, Kraenzlin M, De Greyter Ch, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005; 90: 6014–6021
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale H F, Villuendas G, Botella-Carretero J I, Sancho J, San Millan J L. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003; 46: 625–633
   PubMed Web of Science ®Google Scholar
• Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer A FH, Schill T, Schlosser W H, Brabant G, Schofl C h. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525–532
   PubMed Web of Science ®Google Scholar
• Hotamisligil G S, Shargill N S, Spiegelman B. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259: 87–91
   PubMed Web of Science ®Google Scholar
• Yudkin J S, Stehouwer C D, Emeis J J, Coppack S W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vasc Biol 1999; 19: 972–978
   PubMed Web of Science ®Google Scholar
• Fernandez-Real J M, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M, Richart C, Ricart W. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 2000; 49: 517–520
   PubMed Web of Science ®Google Scholar
• Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker A, Bellastrella A, Carella C, Izzo A. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003; 101: 1177–1182
   PubMed Web of Science ®Google Scholar
• Vgontzas A N, Trakada G, Bixler E O, Lin H M, Pejovic S, Zoumakis E, Chrousos G P, Legro R S. Plasma interleukin-6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006; 55: 1076–1082
   PubMed Web of Science ®Google Scholar
• Gonzalez F, Thusu K, Tomani M, Dandona P. Elevated serum tumor necrosis factor α (TNF-α) in polycystic ovary syndrome (PCOS). Presented at 44th Annual Meeting of the Society of Gynecological Investigation, San Diego, CAUSA, 1997
   Google Scholar
• Sayin N C, Gucer F, Balkanli-Kaplan P, Yuce M A, Ciftici S, Kucuk M, Yardim T. Elevated serum TNF-α levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003; 48: 165–170
   PubMed Web of Science ®Google Scholar
• Engelberts I, Stephens S, Francot G J, van der Linden C J, Buurman W A. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338: 515–516
   PubMed Web of Science ®Google Scholar
• Harborne L R, Sattar N, Norman J E, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005; 90: 4593–4598
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, Hedbreg P, Puukka M, Tapanainen J S. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4649–4654
   PubMed Web of Science ®Google Scholar
• Caballero A E, Delgado A, Aguilar-Salinas C A, Herrera A N, Castillo J L, Cabrera T, Gomez-Perez F J, Rull J A. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004; 89: 3943–3948
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83
   PubMed Web of Science ®Google Scholar
• Trujillo M E, Scherer P E. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167–175
   PubMed Web of Science ®Google Scholar
• Spranger J, Kroke A, Mohlig M, Bergmann M M, Ristow M, Boeing H, Pfeiffer A F. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226–228
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473–2476
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487–37491
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057–1063
   PubMed Web of Science ®Google Scholar
• Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85–89
   PubMed Web of Science ®Google Scholar
• Siemińska L, Marek B, Kos-Kudła B, Niedziolka D, Kajdaniuk D, Nowak M, Glogowska-Szelag J. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest 2004; 27: 528–534
   PubMed Web of Science ®Google Scholar
• Carmina E, Orio F, Palomba S, Longo A R, Cascella T, Colao A, Lombardi G, Rini G B, Lobo R A. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006; 119: 356:e1–e6
   PubMed Web of Science ®Google Scholar
• Orio F, Jr, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, Zullo F, Colao A, Lombardi G, Vettor R. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2619–2623
   PubMed Web of Science ®Google Scholar
• Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in polycystic ovary syndrome. Hum Reprod 2003; 18: 1790–1796
   PubMed Web of Science ®Google Scholar
• Glucelik N E, Aral Y, Serter R, Demir Y, Culha C. Adiponectin is a determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22: 511–515
   PubMedGoogle Scholar